Name | Value |
---|---|
Revenues | 0.3M |
Cost of Revenue | 0.6M |
Gross Profit | -0.3M |
Operating Expense | 10.2M |
Operating I/L | -10.5M |
Other Income/Expense | 1.0M |
Interest Income | 0.4M |
Pretax | -9.3M |
Income Tax Expense | 0.0M |
Net Income/Loss | -9.3M |
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents for diagnostic tests, focusing on the detection and analysis of nucleic acid molecules. The company offers polymerase chain reaction (PCR) diagnostic tests for various diseases including COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus. Additionally, it provides molecular tools for infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co-Diagnostics also offers tests for genetic traits in plant and animal genomes, as well as a portable PCR device for point-of-care and at-home settings.